Trabectedin First Line Therapy In Unfit Sarcoma Study
Status:
Completed
Trial end date:
2016-12-31
Target enrollment:
Participant gender:
Summary
Phase II, non-randomized, two-stage study according to Bryant & Day The study enroll patients
with Metastatic and locally advanced soft tissue sarcoma unfit to receive standard
chemotherapy (doxorubicin/epirubicin and/or ifosfamide)